Atika Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Atika Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30,000	Closed	-$585K	–	97
2018 Q4	$585K	Buy	30,000 +5,000	+20%	+$103K	0.17%	67
2018 Q3	$665K	Buy	+25,000	New	+$816K	0.12%	83
2018 Q2	–	Sell	-113,000	Closed	-$3.69M	–	107
2018 Q1	$3.69M	Buy	+113,000	New	+$4.96M	1.26%	34

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Atika Capital Management's PTLA Position: Q4 2019 in Review

Atika Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 94,000 shares — an estimated $2.52M sold.

Atika Capital Management first reported a position in PTLA in Q1 2015 and held it in 11 quarters. The position peaked at $5.46M in Q3 2015. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

Atika Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Atika Capital Management sold 94,000 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $2.52M.
Atika Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 11 quarters.
Atika Capital Management's Portola Pharmaceuticals, Inc. position peaked at $5.46M in Q3 2015.
224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on Atika Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.